Has the Chinese Clinical Research and Equipment Industry valuation changed over the past few years?

Investors are optimistic on the Chinese Life Sciences Tools and Services industry, and appear confident in long term growth rates. The industry is trading at a PE ratio of 34.6x which is higher than its 3-year average PE of 29.1x. The 3-year average PS ratio of 5.1x is lower than the industry's current PS ratio of 7.6x.

How does Chinese Clinical Research and Equipment compare with similar industries?

There are no additional sub-industries under this industry.

Chinese (SSE) Clinical Research and Equipment Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sat, 19 Sep 2026	CN¥828.9b	CN¥105.6b	CN¥23.1b	80.2x	35.9x	7.9x
Mon, 17 Aug 2026	CN¥843.5b	CN¥104.1b	CN¥23.4b	76x	36x	8.1x
Wed, 15 Jul 2026	CN¥685.2b	CN¥98.8b	CN¥21.9b	68.2x	31.3x	6.9x
Fri, 12 Jun 2026	CN¥523.7b	CN¥98.8b	CN¥21.9b	46.5x	24x	5.3x
Sun, 10 May 2026	CN¥602.8b	CN¥98.7b	CN¥21.7b	57.2x	27.7x	6.1x
Tue, 07 Apr 2026	CN¥585.3b	CN¥94.9b	CN¥20.7b	56.8x	28.3x	6.2x
Thu, 05 Mar 2026	CN¥545.6b	CN¥94.5b	CN¥18.6b	59x	29.4x	5.8x
Sat, 31 Jan 2026	CN¥590.9b	CN¥94.3b	CN¥18.5b	61.8x	31.9x	6.3x
Mon, 29 Dec 2025	CN¥555.5b	CN¥94.3b	CN¥18.5b	61x	30x	5.9x
Wed, 26 Nov 2025	CN¥558.1b	CN¥94.3b	CN¥18.5b	65.7x	30.1x	5.9x
Fri, 24 Oct 2025	CN¥587.9b	CN¥92.1b	CN¥17.4b	68.7x	33.7x	6.4x
Sun, 21 Sep 2025	CN¥628.7b	CN¥92.1b	CN¥17.4b	72.8x	36.1x	6.8x
Tue, 19 Aug 2025	CN¥600.8b	CN¥91.6b	CN¥17.9b	64.3x	33.6x	6.6x
Thu, 17 Jul 2025	CN¥492.7b	CN¥89.8b	CN¥15.4b	51x	32.1x	5.5x
Sat, 14 Jun 2025	CN¥439.9b	CN¥89.8b	CN¥15.4b	47.3x	28.6x	4.9x
Mon, 12 May 2025	CN¥388.3b	CN¥89.3b	CN¥15.1b	45.2x	25.6x	4.3x
Wed, 09 Apr 2025	CN¥358.0b	CN¥88.5b	CN¥14.0b	36.4x	25.5x	4x
Fri, 07 Mar 2025	CN¥440.8b	CN¥89.0b	CN¥11.3b	45x	38.9x	5x
Sun, 02 Feb 2025	CN¥358.6b	CN¥88.1b	CN¥11.2b	37.6x	31.9x	4.1x
Tue, 31 Dec 2024	CN¥371.6b	CN¥87.8b	CN¥11.2b	37.5x	33.2x	4.2x
Thu, 28 Nov 2024	CN¥364.4b	CN¥87.8b	CN¥11.2b	38.8x	32.6x	4.1x
Sat, 26 Oct 2024	CN¥388.5b	CN¥88.3b	CN¥12.3b	37.3x	31.5x	4.4x
Mon, 23 Sep 2024	CN¥284.4b	CN¥88.2b	CN¥12.4b	26.8x	23x	3.2x
Wed, 21 Aug 2024	CN¥274.8b	CN¥87.5b	CN¥12.5b	25.3x	22x	3.1x
Fri, 19 Jul 2024	CN¥281.6b	CN¥88.3b	CN¥13.4b	26x	21x	3.2x
Sun, 16 Jun 2024	CN¥308.1b	CN¥88.3b	CN¥13.4b	27.3x	23x	3.5x
Tue, 14 May 2024	CN¥337.4b	CN¥88.3b	CN¥13.3b	29.5x	25.3x	3.8x
Thu, 11 Apr 2024	CN¥335.6b	CN¥90.3b	CN¥15.0b	33.1x	22.4x	3.7x
Sat, 09 Mar 2024	CN¥346.8b	CN¥90.5b	CN¥15.5b	32.4x	22.4x	3.8x
Mon, 05 Feb 2024	CN¥325.7b	CN¥91.1b	CN¥16.1b	29.5x	20.3x	3.6x
Wed, 03 Jan 2024	CN¥463.2b	CN¥91.1b	CN¥16.1b	38.7x	28.8x	5.1x
Fri, 01 Dec 2023	CN¥531.6b	CN¥91.1b	CN¥16.1b	38.5x	33.1x	5.8x
Sun, 29 Oct 2023	CN¥529.7b	CN¥91.7b	CN¥18.3b	35.8x	28.9x	5.8x
Tue, 26 Sep 2023	CN¥498.2b	CN¥92.0b	CN¥18.3b	33.8x	27.2x	5.4x


CN Market	1.66%
Healthcare	3.06%
Life Sciences	9.00%
Clinical Research and Equipment	9.00%

Company	Last Price	7D	1Y	Valuation
603259 WuXi AppTec	CN¥160.00	5.8% +CN¥25.7b	47.1%	PE23.1x
688114 MGI Tech	CN¥71.97	32.5% +CN¥7.3b	7.4%	PS9.9x
300759 Pharmaron Beijing	CN¥43.30	7.5% +CN¥5.5b	23.7%	PE46.4x
300347 Hangzhou Tigermed Consulting	CN¥57.39	8.7% +CN¥3.8b	-2.3%	PE523.8x
688222 HitGen	CN¥39.97	31.1% +CN¥3.8b	60.3%	PE114.3x

Announcement • Sep 15

MGI Tech Launches VisiOmics And Unveils AI-Enabled Pathology Portfolio At ECP 2026

MGI Tech Co., Ltd. announced the European launch of VisiOmics (PMIF-20RS), a fully automated multiplex immunofluorescence (mIF) staining and imaging system, at the 38th European Congress of Pathology (ECP 2026), held in Stockholm from 12 to 16 September 2026. VisiOmics is a fully automated mIF staining and imaging system that brings high-plex, automated tissue analysis within reach of routine laboratory workflows. VisiOmics enables multiplex detection of protein markers within a single tissue section, allowing researchers to characterize cell populations and investigate their spatial organization within the tissue microenvironment: More than 20-plex detection per run, expandable to more than 100 markers from a single tissue section via cyclic staining. Walk-away automation of the full staining-to-imaging workflow. AI-powered image analysis with FluoXpert Vision — including cell segmentation, phenotyping and spatial analysis — supported by a dedicated AI assistant that lowers the barrier for downstream analysis and data visualization. MGI is also partnering with the Fraunhofer Institute for Integrated Circuits IIS to demonstrate the compatibility of multiplex immunofluorescence images generated by VisiOmics with MIKAIA®, Fraunhofer IIS's image analysis software for digital pathology and spatial biology research. The collaboration aims to show how researchers can use VisiOmics image data within MIKAIA workflows for cell segmentation, phenotyping and spatial analysis. This work supports greater flexibility in downstream analysis, helping laboratories connect automated tissue imaging with tools suited to their research questions. MGI is also presenting Path-P96 WF, a customisable platform for automated multiplex immunofluorescence staining and imaging using standard pathology slides. The system processes up to 32 slides per batch, supports continuous loading and walk-away operation, and enables detection of more than 100 protein markers through cyclic staining. Designed to accommodate different research workflows, Path-P96 WF can be configured for applications in drug discovery and spatial biology, including target validation, spatial phenotyping and image dataset generation for AI-based pathology research. MGI now offers PrepLPS(PrepALL Library Prep Edition), a compact liquid-handling platform for NGS library preparation with eight independent channels (0.5–1,200 µL), AI-based machine vision and ready-to-run workflows. Early Access is now open for European laboratories. AIO (All-in-one) condenses the entire workflow — library preparation, sequencing and reporting — into a single sample-to-result platform: nucleic acid in, report out, in about 11 hours with roughly 10 minutes of hands-on time. AIO is demonstrated live at the booth, and the platform is open for OEM partnerships in Europe. Across the portfolio, AI is built in, not bolted on. Backed by Genoria AI, each platform ships with AI-powered image analysis (FluoXpert Vision on PMIF-20RS), natural-language workflow orchestration on Path-P96 WF, machine-vision monitoring on PrepALL, and intelligent library-pooling strategies on AIO.

Chinese (SSE) Clinical Research and Equipment Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

Investor sentiment improves as stock rises 22%

603259: Future Earnings Will Be Supported By Dividend Payouts And Governance Changes

New major risk - Share price stability

New minor risk - Share price stability

MGI Tech Launches VisiOmics And Unveils AI-Enabled Pathology Portfolio At ECP 2026

New major risk - Revenue and earnings growth

Second quarter 2026 earnings released: EPS: CN¥0.49 (vs CN¥0.42 in 2Q 2025)

Price target increased by 7.7% to CN¥41.08

Second quarter 2026 earnings released: EPS: CN¥0.03 (vs CN¥0.021 in 2Q 2025)